Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients With EGFR-Positive Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients With EGFR-Positive Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gatipotuzumab (Primary) ; Tomuzotuximab (Primary) ; Panitumumab
  • Indications Advanced breast cancer; Colorectal cancer; Gastrointestinal cancer; Gynaecological cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms GATTO
  • Sponsors Glycotope

    • Most Recent Events

    • 08 Jun 2021 Results of final analysis (data cutoff date: Jan 2021) reporting anti-tumor and cytotoxicity activity presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 08 Jun 2021 Safety and tolerability results of the GATTO study presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2021 According to a Glycotope media release, data from this trial were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top